Zylo Therapeutics, Inc.
Greenville, SC
- UEI
- RR11WNA1RBB3
- CAGE
- 80PP9
- Primary NAICS
- 325412 Pharmaceutical Preparation Manufacturing
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 105A Ben Hamby Dr, Greenville, SC 29615, USA
- Website
- zylotherapeutics.com
- Employees
- 1-10
- Estimated annual revenue
- $1M-$10M
- Industry
-
- Consumer Discretionary
- Consumer Durables & Apparel
- Consumer Goods
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Grant awards
Latest 5 listed here. See the rest on GovTribe.
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Nostopharma LLC | Rockville, MD | 541713 Research and Development in Nanotechnology |
| Adepthera LLC | Palo Alto, CA | 325412 Pharmaceutical Preparation Manufacturing |
| Acepre, LLC | Columbia, SC | 325412 Pharmaceutical Preparation Manufacturing |
| Dermaxon LLC | Missoula, MT | — |
| Medchem Partners LLC | Lexington, MA | 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) |
About the company
Zylo Therapeutics, Inc. is a corporate entity registered in SAM.gov, classified as a self-certified small disadvantaged business and for-profit organization located in Greenville, South Carolina. The company appears to be focused on developing innovative microparticle-based topical drug delivery systems for various medical conditions, specializing in creating advanced pharmaceutical formulations that enhance drug penetration and effectiveness. As a manufacturer of goods, Zylo Therapeutics has demonstrated expertise in developing specialized drug delivery technologies that address complex medical challenges across multiple therapeutic areas.
The company has secured multiple federal grant awards from prominent National Institutes of Health agencies, including the National Institute of Allergy and Infectious Diseases, National Institute of Diabetes and Digestive and Kidney Diseases, and National Institute of Arthritis and Musculoskeletal and Skin Diseases. These grants support research and development of microparticle-based topical treatments for conditions such as chronic rhinosinusitis, cutaneous lupus erythematosus, erectile dysfunction, onychomycosis, and other challenging medical issues. Each grant project focuses on developing innovative drug delivery systems using proprietary silica-derived particle technologies, with goals of improving treatment efficacy, reducing side effects, and addressing unmet medical needs. The grants range from $300,000 to support research projects lasting approximately two years, demonstrating Zylo Therapeutics' commitment to advancing targeted therapeutic solutions through advanced microparticle formulation technologies.
Quick answers
Is Zylo Therapeutics, Inc. registered in SAM.gov?
Yes. Zylo Therapeutics, Inc.'s SAM.gov registration is active through May 12, 2027.
What is Zylo Therapeutics, Inc.'s CAGE code?
Zylo Therapeutics, Inc.'s CAGE code is 80PP9, and its Unique Entity ID (UEI) is RR11WNA1RBB3.
What is Zylo Therapeutics, Inc.'s most recent federal award?
Zylo Therapeutics, Inc.'s most recent federal grant award is Development and optimization of a nitric oxide releasing microparticle formulation for the topical treatment of chronic… (R41AI188793), from National Institute of Allergy and Infectious Diseases (NIH), on September 12, 2025.
On GovTribe
See Zylo Therapeutics, Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors